Company / Total Debt
Theravance Biopharma, Inc. Total Debt History
FY2017-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
-
FY2023
5-year range
$0 / $616.3M
FY2019-FY2023
Trend
-
vs FY2022
Sector context
#81 of 83
Health Care
What the data says
Improved from $619M to $0 over the past 3 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 2% in Health CareTop 2% of 83
▼
Key checks
Key Insights
- Peak total debt was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $0 | - |
| FY2022 | - | - |
| FY2021 | $616.3M | -0.5% |
| FY2020 | $619.2M | +36.1% |
| FY2019 | $455.0M | +0.2% |
| FY2018 | $454.4M | +103.1% |
| FY2017 | $223.7M | - |
| FY2016 | - | - |
As of FY2023 · SEC 10-K · Updated Jun 30, 2026